Ieq Capital LLC Takes $908,000 Position in Replimune Group, Inc. $REPL

Ieq Capital LLC acquired a new position in Replimune Group, Inc. (NASDAQ:REPL) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 81,982 shares of the company’s stock, valued at approximately $908,000.

Several other institutional investors have also modified their holdings of the company. BlackRock Inc. acquired a new position in Replimune Group during the second quarter worth about $99,171,000. Balyasny Asset Management L.P. raised its position in Replimune Group by 507.4% in the third quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company’s stock worth $11,012,000 after acquiring an additional 2,195,448 shares in the last quarter. Adage Capital Partners GP L.L.C. acquired a new stake in Replimune Group in the 4th quarter valued at about $17,568,000. Commodore Capital LP bought a new position in shares of Replimune Group during the 4th quarter valued at about $13,851,000. Finally, EcoR1 Capital LLC bought a new position in shares of Replimune Group during the 1st quarter valued at about $7,650,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on REPL. Cantor Fitzgerald reiterated an “overweight” rating on shares of Replimune Group in a report on Wednesday, August 12th. Wall Street Zen upgraded shares of Replimune Group from a “strong sell” rating to a “sell” rating in a report on Saturday, May 23rd. Wolfe Research upgraded shares of Replimune Group to an “outperform” rating in a research report on Tuesday, August 4th. JPMorgan Chase & Co. upped their price target on Replimune Group from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, Wedbush upgraded Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 price objective for the company in a research report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Replimune Group currently has an average rating of “Moderate Buy” and a consensus target price of $12.00.

Replimune Group Price Performance

REPL stock opened at $15.60 on Friday. The company has a current ratio of 5.23, a quick ratio of 5.23 and a debt-to-equity ratio of 1.00. Replimune Group, Inc. has a one year low of $1.50 and a one year high of $16.15. The firm has a market capitalization of $1.46 billion, a PE ratio of -4.95 and a beta of 0.88. The firm has a 50-day moving average of $11.73 and a two-hundred day moving average of $8.29.

Replimune Group (NASDAQ:REPL) last released its earnings results on Friday, August 14th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.03). On average, analysts forecast that Replimune Group, Inc. will post -2.94 earnings per share for the current year.

Insider Buying and Selling

In other Replimune Group news, insider Konstantinos Xynos sold 11,447 shares of Replimune Group stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $148,467.59. Following the transaction, the insider owned 224,215 shares of the company’s stock, valued at $2,908,068.55. The trade was a 4.86% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Sushil Patel sold 39,341 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $12.97, for a total value of $510,252.77. Following the completion of the transaction, the chief executive officer owned 708,151 shares in the company, valued at $9,184,718.47. This represents a 5.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 91,124 shares of company stock valued at $1,149,244. 5.40% of the stock is currently owned by company insiders.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.